157 related articles for article (PubMed ID: 38072426)
1. [Management of iron overload during pregnancy and childbirth in a patient with ferroportin disease].
Ohara K; Tsuge N; Watanabe S; Eda H; Ogasawara F; Kondo T; Yoshida S; Kojima K
Rinsho Ketsueki; 2023; 64(11):1410-1414. PubMed ID: 38072426
[TBL] [Abstract][Full Text] [Related]
2. Long-term phlebotomy successfully alleviated hepatic iron accumulation in a ferroportin disease patient with a mutation in SLC40A1: a case report.
Nishina S; Tomiyama Y; Ikuta K; Tatsumi Y; Toki Y; Kato A; Kato K; Yoshioka N; Sasaki K; Hara Y; Hino K
BMC Gastroenterol; 2021 Mar; 21(1):111. PubMed ID: 33673803
[TBL] [Abstract][Full Text] [Related]
3. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.
Mayr R; Janecke AR; Schranz M; Griffiths WJ; Vogel W; Pietrangelo A; Zoller H
J Hepatol; 2010 Nov; 53(5):941-9. PubMed ID: 20691492
[TBL] [Abstract][Full Text] [Related]
4. Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.
Viveiros A; Panzer M; Baumgartner N; Schaefer B; Finkenstedt A; Henninger B; Theurl I; Nachbaur K; Weiss G; Haubner R; Decristoforo C; Tilg H; Zoller H
Liver Int; 2020 Aug; 40(8):1941-1951. PubMed ID: 32450003
[TBL] [Abstract][Full Text] [Related]
5. Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders.
Kaneko Y; Miyajima H; Piperno A; Tomosugi N; Hayashi H; Morotomi N; Tsuchida K; Ikeda T; Ishikawa A; Ota Y; Wakusawa S; Yoshioka K; Kono S; Pelucchi S; Hattori A; Tatsumi Y; Okada T; Yamagishi M
J Gastroenterol; 2010 Nov; 45(11):1163-71. PubMed ID: 20533066
[TBL] [Abstract][Full Text] [Related]
6. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron.
Koyama C; Wakusawa S; Hayashi H; Ueno T; Suzuki R; Yano M; Saito H; Okazaki T
Intern Med; 2005 Sep; 44(9):990-3. PubMed ID: 16258219
[TBL] [Abstract][Full Text] [Related]
7. Inherited iron overload disorders.
Piperno A; Pelucchi S; Mariani R
Transl Gastroenterol Hepatol; 2020; 5():25. PubMed ID: 32258529
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment of iron overload].
Ruivard M; Lobbes H
Rev Med Interne; 2023 Dec; 44(12):656-661. PubMed ID: 37507250
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological study of Japanese patients with genetic iron overload syndromes.
Hattori A; Miyajima H; Tomosugi N; Tatsumi Y; Hayashi H; Wakusawa S
Pathol Int; 2012 Sep; 62(9):612-8. PubMed ID: 22924847
[TBL] [Abstract][Full Text] [Related]
10. Non-HFE hepatic iron overload.
Pietrangelo A; Caleffi A; Corradini E
Semin Liver Dis; 2011 Aug; 31(3):302-18. PubMed ID: 21901660
[TBL] [Abstract][Full Text] [Related]
11. Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation.
Griffiths WJ; Mayr R; McFarlane I; Hermann M; Halsall DJ; Zoller H; Cox TM
Hepatology; 2010 Mar; 51(3):788-95. PubMed ID: 19937651
[TBL] [Abstract][Full Text] [Related]
12. A novel SLC40A1 p.Y333H mutation with gain of function of ferroportin: A recurrent cause of haemochromatosis in China.
Zhang W; Xu A; Li Y; Zhao S; Zhou D; Wu L; Zhang B; Zhao X; Wang Y; Wang X; Duan W; Wang Q; Nan Y; You H; Jia J; Ou X; Huang J;
Liver Int; 2019 Jun; 39(6):1120-1127. PubMed ID: 30500107
[TBL] [Abstract][Full Text] [Related]
13. Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor.
Praschberger R; Schranz M; Griffiths WJ; Baumgartner N; Hermann M; Lomas DJ; Pietrangelo A; Cox TM; Vogel W; Zoller H
Biochim Biophys Acta; 2014 Sep; 1842(9):1406-12. PubMed ID: 24859227
[TBL] [Abstract][Full Text] [Related]
14. Identification of mutations in SLC40A1 that affect ferroportin function and phenotype of human ferroportin iron overload.
Mayr R; Griffiths WJ; Hermann M; McFarlane I; Halsall DJ; Finkenstedt A; Douds A; Davies SE; Janecke AR; Vogel W; Cox TM; Zoller H
Gastroenterology; 2011 Jun; 140(7):2056-63, 2063.e1. PubMed ID: 21396368
[TBL] [Abstract][Full Text] [Related]
15. Ferroportin disease: pathogenesis, diagnosis and treatment.
Pietrangelo A
Haematologica; 2017 Dec; 102(12):1972-1984. PubMed ID: 29101207
[TBL] [Abstract][Full Text] [Related]
16. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease.
Aigner E; Theurl I; Theurl M; Lederer D; Haufe H; Dietze O; Strasser M; Datz C; Weiss G
Am J Clin Nutr; 2008 May; 87(5):1374-83. PubMed ID: 18469261
[TBL] [Abstract][Full Text] [Related]
17. Hepcidin is a useful biomarker to evaluate hyperferritinemia associated with metabolic syndrome.
Rauber MR; Pilger DA; Cecconello DK; Falcetta FS; Marcondes NA; Faulhaber GAM
An Acad Bras Cienc; 2019 May; 91(2):e20180286. PubMed ID: 31090790
[TBL] [Abstract][Full Text] [Related]
18. Magnetic Resonance Liver Iron Concentration Can Guide Venesection Decision-Making in Hyperferritinemia.
Bhuva M; Patterson I; Godfrey EM; Bowden DJ; Griffiths WJH
Dig Dis Sci; 2023 Jun; 68(6):2704-2709. PubMed ID: 36929239
[TBL] [Abstract][Full Text] [Related]
19. [Genetic iron overloads and hepatic insulin-resistance iron overload syndrome: an update].
Ruivard M
Rev Med Interne; 2009 Jan; 30(1):35-42. PubMed ID: 18584923
[TBL] [Abstract][Full Text] [Related]
20. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Kowdley KV; Modi NB; Peltekian K; Vierling JM; Ferris C; Valone FH; Gupta S
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1118-1128. PubMed ID: 37863080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
